Journey Medical Corp
NASDAQ:DERM

Watchlist Manager
Journey Medical Corp Logo
Journey Medical Corp
NASDAQ:DERM
Watchlist
Price: 9.555 USD 3.19% Market Closed
Market Cap: $202m

Net Margin

-14.6%
Current
Improving
by 9.8%
vs 3-y average of -24.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-14.6%
=
Net Income
$-8.7m
/
Revenue
$59.4m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-14.6%
=
Net Income
$-8.7m
/
Revenue
$59.4m

Peer Comparison

Country Company Market Cap Net
Margin
US
Journey Medical Corp
NASDAQ:DERM
195.8m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
F:1PK
440.4B EUR
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
267.9B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.6B USD
Loading...

Market Distribution

Lower than 72% of companies in the United States of America
Percentile
28th
Based on 15 072 companies
28th percentile
-14.6%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Journey Medical Corp
Glance View

Market Cap
202m USD
Industry
Pharmaceuticals

Journey Medical Corp. operates as a commercial-stage pharmaceutical company, which engages in developing, acquiring, licensing and commercializing of dermatology products. The company is headquartered in Scottsdale, Arizona and currently employs 90 full-time employees. The company went IPO on 2021-11-12. The company is focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company provides nine products that help treat and heal common skin conditions, such as Qbrexza, Accutane, Targadox, Ximino, Exelderm Cream and Solution, Ceracade Skin Emulsion, Luxamend Wound Cream, AMZEEQ and ZILXI. Its product Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, which is an oral isotretinoin drug for the treatment of severe recalcitrant severe acne; Targadox, which is an oral doxycycline drug for adjunctive therapy for acne; Ximino, which is an oral minocycline drug for the treatment of moderate to severe acne; Exelderm Cream and Solution is an antifungal intended for topical use; Ceracade Skin Emulsion is used to treat dry skin conditions; AMZEEQ is used for the treatment of acne and ZILXI, for the treatment of rosacea.

DERM Intrinsic Value
15.917 USD
Undervaluation 40%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-14.6%
=
Net Income
$-8.7m
/
Revenue
$59.4m
What is Journey Medical Corp's current Net Margin?

The current Net Margin for Journey Medical Corp is -14.6%, which is above its 3-year median of -24.4%.

How has Net Margin changed over time?

Over the last 3 years, Journey Medical Corp’s Net Margin has increased from -54.2% to -14.6%. During this period, it reached a low of -63.8% on Jun 30, 2023 and a high of 1.1% on Jun 30, 2024.

Back to Top